Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of avutometinib in healthy adults
NCT05187169Phase 1Completed
- Sponsor
- Verastem Oncology
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avutometinib in Low grade serous ovarian cancer (LGSOC) (2 arms), sponsored by Verastem Oncology. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at 30 days, Area Under the Curve from time zero to 120 hours and 6 more. Started Dec 2021; status: completed.
02
Drugs
avutometinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT05187169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187169.